G6PD (Dublin): chronic non-spherocytic haemolytic anaemia resulting from glucose-6-phosphate dehydrogenase deficiency in an Irish kindred

SHAUN R McCANN, ANNE M SMITHWICK, IAN J TEMPERLEY, AND KEITH TIPTON

From the Department of Haematology, Federated Dublin Voluntary Hospitals, and the Department of Biochemistry, Trinity College, Dublin, Ireland

Summary

A new variant of G6PD associated with chronic non-spherocytic haemolytic anaemia (CNSHA) in an Irish male is described. This variant is unique in that it has a normal electrophoretic mobility, Michaelis constant for G6P and NADP, and a normal pH optimum, together with a marked increase in utilisation of the substrate 2-deoxy glucose-6-phosphate. It is also relatively heat stable when compared with the normal (B) variant. These characteristics distinguish this variant from previously reported variants associated with CNSHA and we have called it G6PD Dublin.

Although over 100 genetic variants of glucose-6-phosphate dehydrogenase (G6PD) have been reported, only three major clinical groups are well recognised. These are the ‘Mediterranean’ variety, the ‘Negro’ variety, and the ‘sporadic’ variety. Sporadic cases of G6PD deficiency associated with chronic non-spherocytic haemolytic anaemia (CNSHA) have been reported in Western Europe, but the disease is not listed as occurring in Ireland. This communication describes G6PD Dublin, a new variant discovered in an Irish male with CNSHA.

Case report

The proband, a 31-year-old male was admitted to hospital for investigation of jaundice. He had had a ‘flu-like’ illness one week before this. Jaundice had also occurred 3 and 5 years previously. There was no history of anaemia in the patient or his family.

On physical examination, he appeared ill, had a pyrexia of 30°C, and had tender hepatomegaly. The spleen was not enlarged. A blood smear showed polychromasia but no spherocytes. Laboratory investigations included a haemoglobin value of 11·2 g/dl, a white blood count of 8·0 × 10⁹/l with a normal differential, a reticulocyte count of 6-0%, and platelets 200 × 10⁹/l. The total serum bilirubin was 41·0 µmol/l and the lactic dehydrogenase was greater than 600 IU/l. The AST (aspartate aminotransaminase) was 93 IU/l (normal 7·0 to 40 IU/l) and alkaline phosphatase was normal. The hepatitis associated antigen was negative. Chest x-ray showed irregular shadowing in the left mid-zone. The Coombs antiglobulin test was negative and the serum haptoglobins were zero. The osmotic fragility was normal and Heinz bodies were not detected. The autohaemolysis test showed 1·87% haemolysis after 48 hours and this was not fully corrected by addition of glucose (1·4%). Urinary haemosiderin was negative and the ascorbate cyanide screening test was strongly positive.

After one week in hospital the patient’s fever abated and his chest x-ray cleared. His steady state haemoglobin since discharge is 13·0 g/dl with a reticulocyte count of 4%.

The laboratory data during and after the patient’s illness indicated a mild haemolytic state (persistent reticulocytosis). The ascorbate cyanide test was positive and this indicated a defect in the red cell hexose monophosphate shunt. The most likely cause of this defect was considered to be G6PD deficiency.

Methods

G6PD purification, determination of enzyme activity, starch gel electrophoresis, and kinetic studies (heat stability, Michaelis constant) were performed according to the methods described by the World...
Health Organization. The partially purified enzyme preparations were stored at 4°C and used within 48 hours. All spectrophotometric assays were made on a Gilford Model 240 with Beckmann DU Monochromater. One unit of G6PD was that amount of enzyme needed to reduce 1 μmol NADP per minute at 25°C. Red cells were assayed for 6-phosphogluconate dehydrogenase by the method of Beutler.

Control or normal G6PD was purified from red cells of laboratory staff in the manner referred to above and is designated Type B.

Results

G6PD Activity
Red cell G6PD activity in the proband was less than 10% of normal (6.1 ± 2.7%).

Electrophoresis
On starch gel the partially purified G6PD from the proband migrated to a similar position to the normal B (100%).

Kinetic Characteristics
The Michaelis constant for glucose-6-phosphate of the partially purified enzyme of the proband was within normal limits, 66 μmol/l. Similarly, the Michaelis constant for NADP was 2.79 ± 0.12 μmol/l, the normal (B) being 2.9 to 4.4 μmol/l.

Utilisation of the substrate analogue 2-deoxyglucose-6-phosphate was, however, consistently markedly increased, 26 ± 2.0% of that of glucose-6-phosphate as shown in table 1.

PH Effect
The effect of pH on the enzyme activity of the mutant G6PD was found to be similar to that of the normal B enzyme with a pH optimum at pH 8.0.

Stability
Partially purified mutant and control enzymes were heated at various temperatures until a temperature was found which caused a loss of about 20% of the activity in 20 minutes. Activity loss was too rapid to be followed above 50°C in the case of the mutant enzyme. However, at 44°C the mutant G6PD was found to be relatively heat stable. The rates of inactivation in the case of the control, diluted control, and mutant enzyme are shown in the figure.

The mutant enzyme was highly unstable in a crude haemolsate and lost its activity within a few hours. On freezing and thawing the haemolsate, loss in activity was almost instantaneous. When mixed with haemolsates from the deficient subject the activity of normal G6PD was not affected. Normal and mutant enzyme, partially purified, remained stable for 3 months when stored at 4°C. The red cell 6-phosphogluconate dehydrogenase (6PGADH) activity was within normal limits.

Discussion

It is now established that G6PD deficiency is by far the most common enzyme abnormality in man. In two of the major clinical groups, the 'Mediterranean' and 'Negro' types, haemolytic anaemia occurs only when the patient is subjected to an oxidant stress, such as oxidant drugs, infections, or in the case of the 'Mediterranean' type, fava beans. In the so-called 'sporadic' type, a chronic haemolytic state may exist in the absence of any oxidant stress and this is referred to as chronic non-spherocytic haemolytic anaemia (CNSHA).

In the patient reported above, the activity of G6PD was abnormally low. Further studies showed it to be different from normal G6PD and from other variants previously described. In table 2, the
characteristics of the mutant G6PD are compared with the normal enzyme and with other variants known to have a utilisation of 2d6PG of 20 to 30% and to be associated with CNSHA. The comparison showed that the mutant is a new and distinct variant of G6PD.

The most distinctive features of the mutant enzyme are its low red cell activity (less than 10% of normal), the relative heat stability, and the marked increase in utilisation of 2 deoxy G6P, when compared with the normal G6PD. Studies of the heat stability of the enzyme at 44°C (figure) indicate that the mutant is more stable than normal G6PD. The increased activity with 2 deoxy G6P is very important in distinguishing the mutant from almost all the known variants of G6PD. It suggests that the mutant may be abnormal at the binding site in the active centre of the enzyme. Because the above properties of the mutant enzyme differ from all known variants of G6PD associated with CNSHA, we have called it G6PD Dublin.

We would like to thank Professor D G Weir for referring this patient for haematological evaluation.

References


Requests for reprints to Dr S R McCann, Department of Clinical Haematology, St James's Hospital, PO Box 580, Dublin 8.
G6PD (Dublin): chronic non-spherocytic haemolytic anaemia resulting from glucose-6-phosphate dehydrogenase deficiency in an Irish kindred.

S R McCann, A M Smithwick, I J Temperley and K Tipton

doi: 10.1136/jmg.17.3.191

Updated information and services can be found at:
http://jmg.bmj.com/content/17/3/191

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/